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greater likelihood of HER2-positive
than HER2-negative tumour cells to
exhibit heightened invasiveness and
metastatic potential5 leads to growth
stimulation by angiogenesis induction
of a greater number of occult
metastatic foci present in patients at
the time of surgery. In both instances,
if angiogenesis induced by endothelial
growth factors released during wound
healing is the most relevant event for
induction of disease recurrence, the
use of trastuzumab to block HER2
activity might not be effective in
preventing relapses. A clinical trial
with perioperative trastuzumab
treatment is ongoing to address this
issue. 
Metastatic growth is a multistep
process, but identification of one key
event might be sufficient to develop
specific therapeutic modalities.
Independent of the actual growth
factors involved in stimulating breast
carcinoma recurrences, surgical
intervention limited only to the extent
deemed mandatory might help in the
control of HER2-positive metastatic
spread.
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Sir—We agree with Elda Tagliabue
and colleagues (Aug 16, p 527)1 that
overexpression of HER2 by breast
carcinoma cells has a role in their
postoperative growth stimulation.
However, we believe the interpretation
of their results is incomplete, since
angiogenesis was not considered as a
mechanism of disease. 
Results of numerous studies suggest
that tumour progression and
development of metastases in breast
cancer are dependent on angiogenesis,
and that HER2 amplification is closely
associated with increased angiogenesis
and expression of vascular endothelial
growth factor (VEGF).2 The blocking
antibody against HER2, trastuzumab,
inhibits VEGF expression and tumour
cell growth.3 Angiogenesis might also
play a part in physiological processes,
involving tissue repair.3 VEGF,
angiopoietin, fibroblast growth factor,
and transforming growth factor  are
among the most potent angiogenic
cytokines in wound angiogenesis.4
Finally, the stimulatory effect of
trauma on angiogenesis could explain
why dormant metastatic tumour cells
proliferate after surgery. The signal for
this action seems to be the release of
angiogenic peptide factors in response
to wounding at the primary and
secondary surgical insults. Enhanced
postoperative angiogenesis and
micrometastatic proliferation might
also be due to resection of the primary
tumour and removal of its inhibitory
effect.5
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Authors’ reply
Sir—Angiogenesis is a key process in
the metastatic progression of breast
carcinomas, and metastases cannot
develop without new vessel formation.
However, vascularisation is necessary
but not sufficient, since proliferation
of tumour cells is also needed. HER2
is an important oncogene in breast
carcinoma pathology, because its
signaling pathway increases both
proliferation and angiogenesis
through induction of VEGF
production.1 After surgery, angiogen-
esis can be increased directly by
endothelial growth factors produced
during the healing process and acting
on endothelial cells in the vicinity of
occult metastatic foci, and indirectly
by VEGF released through HER2
activation on tumour cells.
Accordingly, we noted that all post-
surgical drainage fluids tested
stimulated proliferation not only of
tumour cells through epithelial
growth factors, but also of human
umbilical vein endothelial cells
through endothelial growth factors.
Moreover, induction of proliferation
of both cell types by different drainage
fluids displayed a similar extent of
heterogeneity, suggesting that the
degree of endothelial growth factor,
like the degree of epithelial growth
factor, is related to the extent of
surgery as well as to the age of the
patient.2
The observation that HER2-
positive breast carcinomas, unlike
their HER2-negative counterparts,
show a high peak of early recurrence
after surgery3 raises the possibility that
epithelial growth factors that act on
HER2-positive tumour cells underlie
the stimulation of metastatic growth,
since HER2 activation stimulates
both proliferation and angiogenesis.
Alternatively, as suggested by Mesut
Tez, endothelial growth factors
directly released from the wound
could play the major part, with a
higher likelihood of angiogenic
stimulation in HER2-positive occult
metastatic lesions related, for
example, to a higher prevalence of
endothelial cells, consistent with a
role for HER2 in inducing
angiogenesis.4 Also possible is that the
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